Contact
 

AVAC Says MDP 301 Microbicide Trial Results Disappointing, But Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial

The Microbicides Development Programme announced that its MDP 301 effectiveness trial, which was conducted among almost 9,400 women in four African countries, found no evidence that the PRO 2000 microbicide reduces the risk of HIV infection.

Mitchell Warren, Executive Director of AVAC calls on scientists, funders, advocates and others in the field to ensure that key lessons learned from this trial are incorporated into developing better products and into planning for new trials. The AVAC statement is below and more information about the MDP 301 trial results and PRO 2000 is available at: www.avac.org/pro2000.

AttachmentSize
avac statement on MPD 301 dec 14.pdf179.45 KB
Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account